[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arthritis-psoriatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arthritis-psoriatic":344},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,40,67,78,102,123,143,160,178,197,223,253,280,298,321],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100053934",false,"NCT06641089","Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study With Risankizumab as Active Reference Arm, to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumor Necrosis Factor-α Inhibitors","IZAR-2","Inclusion Criteria:\n\n1. Participants must be ≥18 years of age .\n2. Participants have a confirmed diagnosis of psoriatic arthritis (PsA) per the 2006 Classification for Psoriatic Arthritis (CASPAR) criteria with symptoms for ≥6 months before the Screening Visit.\n3. Participants have active disease (defined by a 68 tender joint count \\[TJC68\\] of ≥3 and a 66 swollen joint count \\[SJC66\\] of ≥3).\n4. Participants have current active plaque psoriasis (PsO) or a dermatologist-confirmed history of plaque PsO.\n5. Participants test negative for both rheumatoid factor and anti-cyclic citrullinated peptide at the Screening Visit.\n6. Participants must have received 1 or more TNFα inhibitors for PsA or PsO and must have experienced an inadequate response to treatment with at least one TNFα inhibitor(s) given at an approved dose for ≥3 months or have stopped treatment due to safety\u002Ftolerability problems after ≥1 administration of a TNFα inhibitor.\n\nExclusion Criteria:\n\n1. Participants with a known hypersensitivity to sonelokimab or any of its excipients.\n2. Participants with a known hypersensitivity, or any contraindication, to risankizumab or any of its excipients or component of the container.\n3. Participants who have a diagnosis of chronic inflammatory conditions other than PsO or PsA.\n4. Participants with a diagnosis of inflammatory bowel disease.\n5. Participants who have experienced a period of ≥3 consecutive weeks of unexplained diarrhea in the 24 weeks before the Baseline Visit.\n6. Participants who have an established diagnosis of arthritis mutilans.\n7. Previous exposure to sonelokimab.\n8. Participants who have ever received biologic immunomodulating agents for PsA or PsO whether investigational or approved, except for those targeting TNFα","ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.",[26],"Arthritis, Psoriatic","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2024-10-15",{"date":35,"type":20},"2027-01-15",{"name":37,"class":38},"MoonLake Immunotherapeutics AG","INDUSTRY",139,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":46,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100642162","NCT07654751","A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically","CNTO1959ISD4001: A Phase 4, Open-Label, Milk-Only Lactation Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically","Inclusion criteria:\n\n* Has an active diagnosis of at least one approved indication for guselkumab (psoriasis, psoriatic arthritis \\[PsA\\], UC and CD) as confirmed by medical records\n* Be medically stable on the basis of medical history review performed at screening. Any abnormalities must be consistent with the underlying illness in the study population and this determination must be recorded in the participant's source documents and initialed by the investigator\n* Currently is on established guselkumab maintenance therapy, that is, has received at least 2 guselkumab subcutaneous (SC) maintenance doses before Day 1\n* Has made the decision to be treated with guselkumab and to breastfeed independently prior to the participant consenting to participate in this study\n* Must be at least 5 weeks postpartum on Day 1\n* Have well-established lactation; participant must be exclusively breastfeeding their infant(s) (or not providing more than 1 supplemental bottle of formula\u002Fday) when enrolled in the study\n* Must plan to continue breastfeeding throughout the duration of the study\n\nExclusion criteria\n\n* Has any current or previous illness that, in the opinion of the investigator, might confound the results of the study or that could prevent, limit, or confound the protocol specified assessments\n* Has history of drug or alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) criteria within 1 year before screening\n* Uses or has used an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 1 month before enrolling in the study\n* Has received or plans to receive any live, attenuated vaccine within 12 weeks prior to administration of guselkumab. Non-live vaccines approved or authorized for emergency use (for example, Coronavirus disease-19 \\[COVID-19\\]) by local health authorities are allowed\n* Has a positive urine pregnancy test on Day 1","FEMALE",{"count":48,"type":20},10,[50],"PHASE4","The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications.",[53,54,55,26],"Psoriasis","Colitis, Ulcerative","Crohn Disease","NOT_YET_RECRUITING","2026-06-12",{"date":59,"type":31},"2026-06-17",{"date":61,"type":20},"2026-06-15",{"date":63,"type":20},"2027-08-31",{"name":65,"class":38},"Janssen Research & Development, LLC",1,{"id":68,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":70,"briefSummary":24,"conditions":71,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":77},"100565354",{"count":19,"type":20},[23],[26],"2026-06-10",{"date":57,"type":31},{"date":33,"type":31},{"date":35,"type":20},{"name":37,"class":38},138,{"id":79,"slug":4,"hasResults":10,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":10,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100567065","NCT06663332","A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants","CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis","TRILOGY","Inclusion Criteria:\n\n* Must have completed the dosing planned in the primary pediatric guselkumab study\n* Must have received benefit from continued guselkumab therapy in the opinion of the investigator\n* Before enrollment, a participant must be either: (a) Not of childbearing potential, OR (b) Of childbearing potential and not sexually active, practicing abstinence or a highly effective method of contraception and agrees to remain on a highly effective method while receiving study intervention and until 12 weeks after the last dose - the end of relevant systemic exposure\n* Parent(s) (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is required from participants who are capable of understanding the nature of the study, typically those aged 7 years and older, to ensure their willingness to participate. An adolescent who provides assent will have the opportunity to sign an adult ICF upon reaching the age of majority, thereby affirming their understanding of the study's purpose and procedures, as well as their willingness to participate.\n\nExclusion Criteria:\n\n* Participant is greater than or equal to (\\>=) 18 years of age and resides in a country where 2 years have elapsed post marketing authorization for the respective adult indication\n* Participant is \\\u003C18 years of age and resides in a county where 2 years have elapsed post marketing authorization for the respective pediatric indication\n* Are pregnant, nursing, or planning pregnancy or fathering a child\n* Have taken any disallowed therapies before the planned first long-term extension (LTE) dose of study intervention\n* Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator\n* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments","3 Years",{"count":87,"type":20},196,[23],"The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).",[91,54,26,92],"Crohns Disease","Arthritis, Juvenile","2026-06-09",{"date":95,"type":31},"2026-06-11",{"date":97,"type":31},"2024-10-29",{"date":99,"type":20},"2032-02-25",{"name":65,"class":38},47,{"id":103,"slug":4,"hasResults":10,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":66},"100633864","NCT07532226","A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants","A Real-World, Prospective Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Patients","PEGASUS","Inclusion criteria:\n\n* Have a confirmed diagnosis of psoriatic arthritis (PsA) as determined by a rheumatologist with reference to ClASsification criteria for Psoriatic ARthritis (CASPAR)\n* Start guselkumab as a first, second, third, or fourth line of disease-modifying antirheumatic drug (bDMARD) therapy for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study\n* Initiating guselkumab treatment according to Summary of Product Characteristics (SmPC) indication\n* The treatment decision must be taken by the participating rheumatologist prior to, and independently of the patient's inclusion into the study, following clinical practice in accordance with local and overarching guidelines and local regulations\n* Must have received the information note, given his\u002Fher oral agreement and has not objected to the collection of his\u002Fher data in accordance with French requirements\n\nExclusion Criteria:\n\n* Have already taken a specific interleukin-23 inhibitor (IL-23i) treatment.\n* Are receiving combination therapy: 2 or more targeted therapies (biotherapy, Janus kinase \\[JAK\\] inhibitor, phosphodiesterase 4 (PDE4) inhibitor) indicated for PsA\u002FPsO at the same time\n* Has a contra-indication to guselkumab according to the SmPC (for hypersensitivity or due to active clinically important infection, example active tuberculosis)\n* Unwilling or unable to participate in long-term data collection\n* Received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before the start of the study ( that is, signing of informed consent)\n* Currently enrolled in any interventional study or any Janssen-Cilag France-sponsored observational clinical study\n* Is under guardianship or curatorship, judicial protection, future protection mandate or under family authorization",{"count":110,"type":20},200,"OBSERVATIONAL","This observational study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).",[26],"2026-06-04",{"date":116,"type":31},"2026-06-05",{"date":118,"type":31},"2026-04-17",{"date":120,"type":20},"2029-12-10",{"name":122,"class":38},"Janssen-Cilag Ltd.",{"id":124,"slug":4,"hasResults":10,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":134,"conditions":135,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100617688","NCT07321873","A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis","A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-88545223 For the Treatment of Participants With Active Psoriatic Arthritis","VELOTA","Inclusion Criteria:\n\n* Have a diagnosis of psoriatic arthritis (PsA) for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening\n* Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (Week 0\u002FDay 1) based on the 66\u002F68 joint assessment; AND (b) C-reactive protein (CRP) greater than or equal to (\\>=) 0.1 milligrams per deciliter (mg\u002FdL) at screening from the central laboratory\n* Have \\>= 1 of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis\n* Have active plaque psoriasis with at least one psoriatic plaque of \\>= 2 centimeter (cm) diameter or nail changes consistent with psoriasis\n* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention\n\nExclusion Criteria:\n\n* Has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)\n* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (except PsA), psychiatric, genitourinary, or metabolic disturbances\n* Has suspected or known allergies, hypersensitivity, or intolerance to JNJ-88545223 or excipients used in the investigational medicinal product (IMP), including placebo (JNJ-88545223 investigator's brochure); or has a history of severe allergic reaction, angioedema, or anaphylaxis to drugs or food\n* Has fibromyalgia or osteoarthritis symptoms that, in the opinion of the investigator, would have potential to interfere with efficacy assessments\n* Currently has a malignancy or has a history of malignancy within 5 years prior to screening",{"count":131,"type":20},240,[133],"PHASE2","The purpose of this study is to evaluate how well the study drug JNJ-88545223 works compared with a placebo (an inactive substance) in adults with active psoriatic arthritis (PsA). The study aims to see whether treatment with JNJ-88545223 can help reduce the signs and symptoms of PsA and improve joint and skin health.",[26],{"date":116,"type":31},{"date":138,"type":31},"2026-01-15",{"date":140,"type":20},"2027-08-02",{"name":65,"class":38},68,{"id":144,"slug":4,"hasResults":10,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":153,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":159},"100609918","NCT07220824","A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting","GUselkumab for the Treatment of PsA: Effectiveness Results by Ultrasound","GURU","Inclusion criteria:\n\n* Diagnosis of PsA as per CASPAR classification criteria for at least six months with active PsA defined as a tender joint count (TJC) greater than or equal to (\\>=) 3\u002F68 and a swollen joint count (SJC) \\>= 3\u002F66 at baseline, or C-reactive protein (CRP) \\>=0.3 milligrams per deciliter (mg\u002FdL) if TJC and\u002For SJC are less than (\\\u003C) 3\n* a) Total synovitis power doppler ultrasound (PDUS) score \\>=2 and inflammation related to power doppler (PD) signal \\>=2 for at least 1 affected joint of 48 joints at the baseline visit (before first Guselkumab administration), or b) Total synovitis PDUS score \\>=2 and inflammation related to PD signal \\>=1 for at least 2 affected joints of 48 joints at the baseline visit (before first Guselkumab administration)\n* Start guselkumab for the indication of PsA as part of standard clinical practice at the time of enrollment into the observational study or within a maximum of two weeks after the initial baseline visit\n* Participants must be biologic-naïve or previously exposed to only one biologic Disease-Modifying Antirheumatic Drugs (bDMARD) and\u002For apremilast\u002Fdeucravacitinib\n* At least one clinically involved enthesitis site, defined by SPARCC index \\>= 1, and one imaging-detected enthesitis site at baseline\n\nExclusion criteria:\n\n* Previous exposure to Guselkumab or to more than one bDMARD for any indications\n* Prior treatment with Janus kinase (JAK) inhibitors\n* Contraindications to Guselkumab as per the summary of product characteristics (SmPC)\n* Current enrollment in other investigational study or participation in other investigational study completed from less than 30 days\n* Current enrollment in an observational study with Guselkumab sponsored or managed by sponsor",{"count":110,"type":20},"The purpose of this study is to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches) using muscoloskeletal ultrasound (MSUS) in a real-world setting.",[26],{"date":116,"type":31},{"date":155,"type":31},"2025-12-04",{"date":157,"type":20},"2027-09-30",{"name":65,"class":38},21,{"id":161,"slug":4,"hasResults":10,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":21,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":48},"100603783","NCT07141004","A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)","A Phase-IV, Multicenter, Non-Comparative, Open-Label Study Evaluating the Safety and Efficacy of Guselkumab Administered Subcutaneously in the Treatment of Indian Patients With Psoriatic Arthritis","Inclusion Criteria:\n\n* Participants who have definite diagnosis of active psoriatic arthritis (PsA) (according to the ClASsification criteria for Psoriatic Arthritis \\[CASPAR\\]) prior to the first administration of study drug and have at least 1 of the PsA subsets: distal interphalangeal joint arthritis, polyarticular arthritis with the absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis\n* Participants who are negative for rheumatoid factors\n* Participants having inadequate response (defined by presence of active arthritis \\[presence of any swollen or any tender joint\\]) to standard therapies for 3 months at the highest recommended dose (e.g., conventional disease-modifying antirheumatic drugs \\[DMARDs\\] including methotrexate, apremilast, or nonsteroidal anti-inflammatory drugs \\[NSAIDs\\]), including biologics naïve patient or have failed, or were intolerant to one or more biological treatments \\[anti-TNF\u002FIL-17i\\]\n* Participants are considered eligible per the following Tuberculosis (TB) screening criteria:\n\n  1. Have no history of TB prior to screening AND\n  2. Have no signs or symptoms suggestive of active TB upon medical history and\u002For physical examination AND\n  3. Have had no recent close contact with a person with active TB, or if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation and, if warranted, receive appropriate treatment for latent TB prior to or simultaneously with the first administration of study drug AND\n  4. Within 6 weeks prior to the first administration of study drug, have a negative QuantiFERON- TB Gold and a negative tuberculin skin test result, OR have a newly identified positive QuantiFERON-TB Gold or tuberculin skin test result during screening in which active TB has been ruled out and for which appropriate treatment for latent TB has been initiated either prior to or simultaneously with the first administration of study drug AND\n  5. Have a chest radiograph (both posterior-anterior and lateral views), taken within 3 months prior to the first administration of study drug and read by a qualified radiologist, with no evidence of current active TB or old inactive TB\n* Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead ECG\n* A woman of childbearing potential must have a negative highly sensitive serum beta-hCG at screening visit\n\nExclusion Criteria:\n\n* History of latent or active granulomatous infection prior to screening\n* Have a known clinically significant hypersensitivity to guselkumab or to any of the excipients\n* Have had a serious infection, or have been hospitalized for an infection, or have been treated with intravenous (IV) antibiotics for an infection within 2 months prior to first administration of study intervention\n* Has any known malignancy or has a history of malignancy, or a history of lymphoproliferative disease\n* Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months before the first administration of study intervention, during the study, or within 6 months after the last administration of study intervention",{"count":167,"type":20},100,[50],"The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.",[26],{"date":116,"type":31},{"date":173,"type":31},"2025-08-12",{"date":175,"type":20},"2027-09-11",{"name":177,"class":38},"Johnson & Johnson Private Limited",{"id":179,"slug":4,"hasResults":10,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":196},"100578140","NCT06807424","A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis","A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis","ICONIC-PsA 2","Inclusion Criteria:\n\n* Have active psoriatic arthritis (PsA) despite current or previous use of greater than or equal to (\\>=) 1 of the following: a. Non-biologic disease-modifying antirheumatic drug (DMARD) therapy; b. Apremilast therapy; c. Biologic-agent (limited to only 1)\n* Have a diagnosis of PsA for at least 3 months before the first administration of study intervention and meet classification criteria for Psoriatic Arthritis (CASPAR) at screening\n* Have active PsA as defined by: (a) At least 3 swollen joints and at least 3 tender joints at screening and at baseline (b) C-reactive protein (CRP) \\>= 0.1 milligrams per deciliter (mg\u002FdL) at screening from the central laboratory\n* Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis\n* Have active plaque psoriasis with at least one psoriatic plaque of \\>= 2 cm diameter or nail changes consistent with psoriasis\n* A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test (Beta-hCG) at screening and a negative urine pregnancy test at Week 0 prior to administration of study intervention\n\nExclusion Criteria:\n\n* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic (with the exception of PsA), psychiatric, genitourinary, or metabolic disturbances\n* Currently has a malignancy or has a history of malignancy within 5 years prior to screening\n* Has known allergies, hypersensitivity, or intolerance to icotrokinra or its excipients\n* Has other inflammatory diseases that might confound the evaluations of benefit of icotrokinra therapy, including but not limited to rheumatoid arthritis (RA), systemic lupus erythematosus, or Lyme disease\n* Participants with fibromyalgia or osteoarthritis symptoms that, in the investigator's opinion, would have potential to interfere with efficacy assessments",{"count":186,"type":20},750,[23],"The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.",[26],{"date":116,"type":31},{"date":192,"type":31},"2025-01-09",{"date":194,"type":20},"2028-10-18",{"name":65,"class":38},216,{"id":198,"slug":4,"hasResults":10,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":66},"100571308","NCT06718569","Pain in Inflammatory Joint Diseases","Advancing the Understanding of Pain Mechanisms in Inflammatory Arthritis Towards Precision Pain Management","Nor-Pain","Inclusion Criteria:\n\n* All patients who initiate or switch biological or targeted synthetic DMARDs\n\nExclusion Criteria:\n\n* None",{"count":205,"type":20},350,"Our primary objective is to better understand the etiology and consequences of chronic paint by using an explorative approach to identify phenotypes and endotypes of patients with inflammatory joint diseases, with a special focus on central sensitization and cognitive functioning as a key element in chronic pain. We will also examine the risk factors and clinical impact of these factors on pain, disease activity and treatment effects in a longitudinal study of patients with inflammatory joint disesases.",[208,209,210,211,26,212],"Arthritis","Arthritis, Juvenile Idiopathic","Arthritis,Rheumatoid","Arthritis, Reactive","Spondyloarthritis (SpA)","2026-04-07",{"date":215,"type":31},"2026-04-13",{"date":217,"type":31},"2025-11-11",{"date":219,"type":20},"2027-11",{"name":221,"class":222},"Diakonhjemmet Hospital","OTHER",{"id":224,"slug":4,"hasResults":10,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":231,"conditions":232,"keywords":239,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":66},"100580823","NCT06842316","Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","In Vitro Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","pCB-IMIDs","Inclusion Criteria:\n\n1. Male or female ≥ 18 years old\n2. Diagnosis confirmed by a rheumatologist of RA or spondyloarthropathy (with or without IBD) or psoriatic arthritis (with or without active psoriasis) or systemic lupus erythematosus or Sjögren's disease\n3. Patient who has expressed consent to participate in the study\n4. Patients affiliated to social security\n5. Treatments authorized as part of routine care: non-steroidal anti-inflammatory drugs (NSAIDs), level 1 to 3 analgesics, local corticosteroids, oral corticosteroid therapy (daily dose ≤15 mg\u002Fd), 5-aminosalicylic acid, salazopyrine, methotrexate, leflunomide, hydroxychloroquine, biotherapies and targeted therapies.\n\nExclusion Criteria:\n\n1. Patient who received intravenous corticosteroid therapy less than 4 weeks ago\n2. Patient receiving oral corticosteroid therapy with a daily dose \\>15 mg\u002Fday\n3. Consumption of CBD and\u002For recreational cannabis and\u002For positive saliva test for cannabis consumption and\u002For CBD\n4. Pregnant and lactating women\n5. Persons under guardianship or curatorship",{"count":167,"type":20},"Cannabis, in addition to its psychotropic properties, could have anti-inflammatory and immunomodulatory effects. Phytocannabinoids (pCBs) are a group of molecules naturally secreted by the cannabis plant. The major pCBs are cannabidiol (CBD) and Δ9-tetrahydrocannabinol Δ9 (THC). Only THC has psychotropic effects, which CBD does not have. Alongside these two main components, there is a wide variety of other molecules, such as other pCBs and terpenes which could increase the effects on immune system through synergistic interactions between these different compounds (\"entourage effect\").In vivo, pCBs essentially interfere with the endocannabinoid system, acting on many ubiquitous receptors, present on a significant number of different cell types. Numerous published studies show that pCBs have immunomodulatory and anti-inflammatory properties by acting on several of these receptors, whether through modulation of the immune response of different cell types, effects on cytokine networks, reduction of innate and adaptive responses and\u002For impact on cell survival or death (autophagy, proliferation\u002F apoptosis). The Immune-Mediated Inflammatory Diseases (IMIDs) affect 5 to 7% of the general population in Western countries, involve different organs (joints, skin, digestive tract) but share the same inflammatory mechanisms resulting from a dysregulation of the immune response. Our research focuses on the identification of the most effective phytochemical profile of pCBs, allowing an optimal effect on chronic inflammatory pathologies of interest among immune-mediated chronic inflammatory diseases (IMIDs). The pCB-IMIDs project is therefore part of an innovative translational project, around new therapeutic applications of medical cannabis (CannAppIMIDs). In our study, we will include 100 patients with one of IMIDs among Rheumatoid Arthritis, spondylarthritis, psoriatic arthritis, Sjogren disease and systemic lupus, at different stage and with different treatments. After patient's consent we will collect for research purposes an additional 40 ml of blood during a routine care blood test. Mononuclear and polynucleated blood cells will be exposed in vitro to different full-spectrum pCB extracts (full spectrum extract) including a CBD dominant and low THC extract (\\\u003C0.2%), 1 dominant THC extract, 1 balanced THC\u002FCBD extract and 1 dominant CBG extract. In this cross-sectional study, our objective will be to assess the biological effects of different pCB compositions on inflammatory profiles (concentrations of pro and anti-inflammatory cytokines and chemokines) and modulations of expression profiles (autophagy, apoptosis, and cannabinoid receptor expression profile).",[233,234,235,26,236,237,238],"Inflammatory Disorder of Immune System","Spondylitis, Ankylosing","Arthritis, Rheumatoid","Inflammatory Bowel Diseases","Sjogren's Syndrome","Lupus Erythematosus, Systemic",[240,241,242,243],"IMIDs","phytocanabinoid","inflammatory effect","blood cells","2025-12-22",{"date":246,"type":31},"2025-12-30",{"date":248,"type":31},"2025-04-10",{"date":250,"type":20},"2027-04-09",{"name":252,"class":222},"Centre Hospitalier Régional d'Orléans",{"id":254,"slug":4,"hasResults":10,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":279},"100536058","NCT06259890","Influence of Sodium Intake in spondyLoarthriTes","Sodium Intake in spondyLoarthriTes: Analysis of the Influence on the Activity of the Disease and the Therapeutic Response to Anti IL-17A Agents.","SALT","Inclusion Criteria:\n\n* patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis\n* women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)\n\nExclusion Criteria:\n\n* patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.\n* current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old.\n* patients on systemic corticosteroids with corticosteroid therapy \\> 10 mg prednisone equivalent\n* pregnant woman","80 Years",{"count":262,"type":20},250,[264],"NA","The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.",[267,26],"Spondyloarthritis, Axial",[269],"Sodium intake","2025-07-04",{"date":272,"type":31},"2025-07-09",{"date":274,"type":31},"2024-01-30",{"date":276,"type":20},"2027-05",{"name":278,"class":222},"Centre Hospitalier Universitaire de Besancon",4,{"id":281,"slug":4,"hasResults":10,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":4,"eligibilityCriteria":285,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":286,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":66},"100418678","NCT04731831","Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.","Characterization of Immunogenicity of Tumor Necrosis Factor Inhibitors in Arthritis Patients With Poorer Treatment Response Due to Gender, Obesity and Smoking Status.","Inclusion Criteria:\n\n* Patients \\> 18 years\n* Diagnosed with RA, PsA or AS.\n* Starting treatment with infliximab or adalimumab.\n* Co- treatment with csDMARD or glucocorticoid is acceptable.\n* No new bDMARD is initiated at the time of sampling.\n\nExclusion Criteria:\n\n\\-",{"count":287,"type":20},120,"The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.",[235,26,234],"2024-06-27",{"date":292,"type":31},"2024-06-28",{"date":294,"type":31},"2020-08-01",{"date":246,"type":20},{"name":297,"class":222},"Aalborg University Hospital",{"id":299,"slug":4,"hasResults":10,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":304,"enrollmentInfo":305,"targetDuration":307,"studyType":111,"phases":4,"briefSummary":308,"conditions":309,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":66},"100507129","NCT05883371","IMPACT - AndHealth Autoimmune Research Registry","Investigating Mechanisms of Participatory Autoimmune Condition Treatment (IMPACT): An Outcomes Research Registry of a Comprehensive Approach to Autoimmune Disorders","Inclusion Criteria:\n\n1. Adults 18 to 70 years of age\n2. Able to understand and write English\n3. Voluntarily consent to the study and understand its nature and purpose including potential risks and side effects\n4. Documented diagnosis and current use\u002Frecommendation for biologic or DMARD medications to treat rheumatoid arthritis, psoriatic arthritis, psoriasis, or ankylosing spondylitis.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or planning to become pregnant in the next 12 months\n2. Advanced liver or kidney disease\n3. Previous organ transplant or awaiting organ transplant\n4. Actively being treated for cancer\n5. Poorly-controlled mental illness (i.e., schizophrenia, bipolar, current eating disorder)\n6. Has a terminal illness\n7. Current opioid use","70 Years",{"count":306,"type":20},2500,"5 Years","This is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach (\"AndHealth program\") for autoimmune disorders. This approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed physician with the support of health coaches. While protocol guidance is provided, the therapeutic approach is personalized to the individual needs of patients. The autoimmune disorders of focus in this registry include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. A variety of validated labs, patient-reported outcomes, and medication usage will be assessed among participating patients over a period of up to five years to evaluate the long-term effectiveness of this approach.",[235,26,53,310,311],"Ankylosing Spondylitis","Autoimmune Diseases","2023-06-28",{"date":314,"type":31},"2023-06-29",{"date":316,"type":31},"2023-06-08",{"date":318,"type":20},"2028-05-22",{"name":320,"class":38},"AndHealth",{"id":322,"slug":4,"hasResults":10,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":111,"phases":4,"briefSummary":329,"conditions":330,"keywords":332,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":343},"100489801","NCT05657847","Novel Complex Radiodiagnostics of Peripherial Arthropathies","Inclusion Criteria:\n\n* Rheumatoid arthritis (EULAR\u002FACR Criteria) \u002F Psoriatic arthritis (CASPAR Criteria)\u002F Crystal arthropathies\n* signed informed consent\n\nExclusion Criteria:\n\n* age: \\\u003C18 years, \\> 100 years\n* pregnant\n* breastfeeding","100 Years",{"count":328,"type":20},500,"Chronic peripherial arthritides are common diseases with soaring public health consequences. Our goal is to assess the role of photon-counting detector computed tomography in the diagnostics of peripherial arthropathies.",[235,26,331],"Crystal Arthropathies",[333],"photon-counting detector computer tomography, magnetic resonance imaging, radiography, rheumatoid arthritis, psoriatic arthritis, crystal arthropathies","2022-12-12",{"date":336,"type":31},"2022-12-20",{"date":338,"type":31},"2022-03-07",{"date":340,"type":20},"2027-02-01",{"name":342,"class":222},"Semmelweis University",3,""]